G patch domain-containing protein 2 (GPATCH2)

G patch domain-containing protein 2 (GPATCH2) is characterized by a conserved G-patch domain, which is thought to confer RNA-binding capabilities and facilitate protein-protein interactions, especially with RNA-dependent ATPases like DHX15 (hPrp43). It is significantly overexpressed in breast cancer and undetectable except in testis among normal human tissues. Functional studies reveal that GPATCH2 promotes the growth of tumor cells, possibly by enhancing ribosome biogenesis and spliceosomal disassembly—critical processes for rapidly dividing cells. Its interaction with DHX15 boosts ATPase activity, linking GPATCH2 to RNA metabolism and ribonucleoprotein complex processing. As a cancer/testis antigen, GPATCH2 represents an attractive but relatively unexplored target for cancer therapy due to its tissue-restricted expression and role in tumor cell proliferation[1][4][6][7].

Other names

GPATCH2GPATC2FLJ10252CT110PPP1R30Pfa1cancer/testis antigen 110protein phosphatase 1, regulatory subunit 30

RNA interference (siRNA against GPATCH2 suppresses expression and inhibits cancer cell growth) Inhibition of GPATCH2–hPrp43 interaction (proposed therapeutic strategy, not yet drug validated)